Forty-four pediatric patients with nonurinary tract infections were treated with the new orally administered cephalosporin, cephaloglycin. Seventeen of the 19 patients with streptococcal pharyngitis, 8 of 10 with otitis media, and 13 of 14 with skin or subcutaneous tissue infections were considered to have been cured. One patient who had seven previous episodes of pyelonephritis was successfully treated and tolerated six months of therapy without ill effect. Twenty of the 44 patients developed mild to moderate loose stools or "diarrhea." In no case was this severe enough to necessitate cessation of therapy. Serum levels of cephaloglycin vary but levels usually do not exceed 2μg/ml. Though cephaloglycin has been approved for use in urinary tract infections, evidence of efficacy for this antibiotic in nonurinary infections is not extensive enough to be appropriately convincing at this time.